Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell
- PMID: 18778291
- PMCID: PMC2669823
- DOI: 10.1111/j.1365-2567.2008.02910.x
Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell
Abstract
The polyclonal cytokine-induced killer (CIK) cells exhibit potent cytotoxicity against a variety of tumour cells including autologous and allogeneic acute myeloid leukaemic (AML) targets. At maturity, three lymphocyte subsets: CD3(-) CD56(+), CD3(+) CD56(-) and CD3(+) CD56(+), constitute the bulk of the CIK cell culture. The CD3(-) CD56(+) subset behaves like classical natural killer (NK) cells where cytotoxicity is potentiated by blocking the human leucocyte antigen Class I molecules in the AML targets. Both the CD3(+) CD56(+) and CD3(+) CD56(-) subsets, though known to kill autologous and allogeneic targets to a comparable degree and therefore non-major histocompatibility complex (MHC)-restricted, nevertheless require the presence of the MHC molecule on the target, which interacts with their CD3-T-cell receptor complex. Although CIK cells are often termed 'NK-like' T cells, we have demonstrated that the well-characterized NK receptors KIR, NKG2C/E, NKG2D and DNAM-1 are not involved in the process of AML recognition for the CD3(+) CD56(-) and CD3(+) CD56(+) subsets. The CD3(+) CD56(+) and CD3(+) CD56(-) subsets express a polyclonal and comparable TCRVbeta repertoire in a Gaussian distribution. The CD3(+) CD56(+) subset kills AML targets more efficiently than its CD3(+) CD56(-) counterpart because of the presence of a higher proportion of CD8(+) cells. The CD3(+) CD56(+) subset comprise more terminally differentiated late effector T cells that bear the CD27(+) CD28(-) or CD27(-) CD28(-) phenotype, with a higher granzyme A content. In comparison, the phenotype of the CD3(+) CD56(-) subset is consistent with early effector T cells that are CD27(+) CD28(+) and CD62L(+), known to be less cytotoxic but possess greater proliferative potential.
Figures













Similar articles
-
Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.Blood. 2011 Sep 22;118(12):3301-10. doi: 10.1182/blood-2011-02-336321. Epub 2011 Aug 5. Blood. 2011. PMID: 21821703
-
Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia.Leuk Lymphoma. 2003 Sep;44(9):1457-62. doi: 10.3109/10428190309178764. Leuk Lymphoma. 2003. PMID: 14565644 Review.
-
The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.Hum Immunol. 2015 May;76(5):385-91. doi: 10.1016/j.humimm.2014.09.021. Epub 2014 Oct 8. Hum Immunol. 2015. PMID: 25305457 Review.
-
Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.Blood. 1998 Nov 1;92(9):3318-27. Blood. 1998. PMID: 9787169
-
A novel mechanism of antitumor response involving the expansion of CD3+/CD56+ large granular lymphocytes triggered by a tumor-expressed activating ligand.Leukemia. 2002 May;16(5):855-60. doi: 10.1038/sj.leu.2402488. Leukemia. 2002. PMID: 11986947
Cited by
-
Cytokine-induced killer cells: A novel immunotherapy strategy for leukemia.Oncol Lett. 2015 Feb;9(2):535-541. doi: 10.3892/ol.2014.2780. Epub 2014 Dec 8. Oncol Lett. 2015. PMID: 25621022 Free PMC article.
-
Immunophenotype and antitumor activity of cytokine-induced killer cells from patients with hepatocellular carcinoma.PLoS One. 2023 Jan 4;18(1):e0280023. doi: 10.1371/journal.pone.0280023. eCollection 2023. PLoS One. 2023. PMID: 36598909 Free PMC article.
-
Innovative Clinical Perspectives for CIK Cells in Cancer Patients.Int J Mol Sci. 2018 Jan 25;19(2):358. doi: 10.3390/ijms19020358. Int J Mol Sci. 2018. PMID: 29370095 Free PMC article. Review.
-
SMAC Mimetic BV6 Enables Sensitization of Resistant Tumor Cells but also Affects Cytokine-Induced Killer (CIK) Cells: A Potential Challenge for Combination Therapy.Front Pediatr. 2014 Jul 18;2:75. doi: 10.3389/fped.2014.00075. eCollection 2014. Front Pediatr. 2014. PMID: 25101252 Free PMC article.
-
Cytokine-induced killer cells hunt individual cancer cells in droves in a mouse model.Cancer Immunol Immunother. 2017 Feb;66(2):193-202. doi: 10.1007/s00262-016-1934-2. Epub 2016 Nov 25. Cancer Immunol Immunother. 2017. PMID: 27888293 Free PMC article.
References
-
- Schmidt-Wolf IGH, Lefterova P, Johnston V, et al. Sensitivity of multidrug-resistant tumour cell lines to immunologic effector cells. Cell Immunol. 1996;169:85–90. - PubMed
-
- Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994;153:1687–96. - PubMed
-
- Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukemic samples with in vitro cytotoxicity against autologous and allogeneic leukemic blasts. Br J Hematol. 2002;116:78–86. - PubMed
-
- Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS. Expansion of Philadelphia chromosome-negative CD3+CD56+ cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood. 1998;92:3318–27. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials